Kristina Masson, Ph.D., is Co-Founder and EVP, Business Operations at Acrivon Therapeutics, Inc. and President and CEO of the company´s research subsidiary Acrivon AB located in Medicon Village, Sweden. Here she has established all infrastructure, heads all operations, and runs the phospho-proteomic discovery hub and early drug programs for the company’s proprietary AP3 platform. In 2016 she founded and operated OncoSignature AB, a small biotech company focused on identifying predictive biomarkers for clinical-stage cancer therapeutics for US companies. OncoSignature’s business was subsequently acquired by Acrivon AB. Prior to that she was Principal Scientist at Merrimack Pharmaceuticals, Cambridge, MA where she co-led, managed, and participated in cross-functional teams in both preclinical and clinical-stage therapeutic antibody programs, designing projects to identify predictive biomarkers, combination strategies and resistance mechanisms. Before joining Merrimack Pharmaceuticals, Kristina was a Post-Doctoral Fellow in the Golub lab at the Broad Institute of MIT and Harvard, developing assays for novel therapeutics and automated high-throughput drug screening approaches centered around synthetic lethality in cancer. Kristina received her MSc and Ph.D. from Lund University, Sweden.